Janus Henderson rolls out global life sciences fund

The new offering aims to outperform the MSCI World Health Care Index


Janus Henderson has launched the Global Life Sciences Equity Fund.

The new offering aims to outperform the MSCI World Health Care Index by at least 2% per annum over a market cycle by investing in companies addressing unmet medical needs, or aimed at maintaining or improving quality of life.

The asset manager said the fund is an extension of the existing global life sciences strategy.

It will be managed by Andy Acker and Dan Lyons. Acker leads the firm’s health care research team and has been managing the global life sciences strategy since 2007. The pair will be supported by a team of sector specialists with scientific backgrounds who have more than 100 years of combined healthcare investment experience. 

See also: Calastone: Equities funds shed £1.19bn in August as money markets soak up more cash

The portfolio managers will adopt a diversified approach across market capitalisations, geographies and the primary sub-sectors of healthcare including investments in pharmaceuticals, biotechnology, healthcare services, and medical devices. They will seek to deliver exposure to innovation in healthcare, and the sector’s accelerating growth opportunities.

Key factors such as ageing populations and growing wealth are increasing demand for healthcare, while advancements in technology, and research and development, are accelerating the speed to market of new products, according to Janus Henderson.

The fund will be available as an OEIC in the UK to retail, wholesale and institutional investors. It will be managed as part of the existing and long-standing Irish and US Mutual vehicles. 

See also: Are US equities overvalued, or are valuations just high?

Acker said: “Unique to the healthcare sector is the disparity of returns between the best performing stocks and the worst – it is the widest of any sector. At the same time, large biopharmaceutical and managed care companies can offer steady returns amid periods of market volatility, thanks to their stable free cash flows.

“Our Global Life Sciences team – whose members include a practicing physician and analysts with biomedical PhDs – focuses on understanding both the science and commercial opportunities throughout the sector. This combination of expertise and experience makes our team well equipped for this highly complex and dynamic sector, as we aim to provide both growth and capital preservation for investors.”

PA EVENT: Autumn CongressSeptember 27th– 29th | RSVP via email

Hosted at The South Lodge Hotel. Transport and accommodation will be provided for the duration of the event.

Our Autumn Congress will serve as a comprehensive platform for discussing the key trends, challenges, and innovations shaping the wealth management landscape. It will bring together thought leaders and industry professionals for enlightening discussions and networking opportunities. Register link | 

Sponsors include Alliance Bernstein, Alger, Boston Partners, Baillie Gifford, CCLA, Janus Henderson, GAM, Jupiter AM and much more! Please see the full line-up on our website: AC2023

Latest Stories